Number of antibiotics in clinical pipeline targeting WHO pathogens by type 2023

Published by
Matej Mikulic,
Jul 22, 2024

In 2023, there were 15 β-lactam + BLI antibiotics in clinical phases targeting pathogens which are on the WHO priority pathogens list, while there was one tetracycline antibiotic targeting these pathogens. This statistic illustrates the number of antibiotics in the clinical pipeline worldwide targeting WHO priority pathogens.

Number of antibiotics in the clinical pipeline worldwide targeting WHO priority pathogens in 2023, by type

CharacteristicNumber of antibiotics
β-lactam + BLI 15
Polymyxin 3
Novel bacterial type II topoisomerase inhibitors (NBTIs) 3
Host defence peptides 2
Macrolide/ketolide 2
Tethered macrocyclic peptides 1
Tetracycline 1
Aminoglycoside 1
FabI inhibitor 1
FtsZ inhibitor 1
ATP production disruptors 1
Antibiotic hybrid 1
Showing entries 1 to 12 (12 entries in total)
Created with Highcharts 7.2.2Number of antibiotics15153333222211111111111111β-lactam + BLIPolymyxinNovel bacterial type II topoisomerase inhibitors (NBTIs)Host defence peptidesMacrolide/ketolideTethered macrocyclic peptidesTetracyclineAminoglycosideFabI inhibitorFtsZ inhibitorATP production disruptorsAntibiotic hybrid
01234567891011121314151617

© Statista 2025
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

June 2024

Region

Worldwide

Survey time period

2023

Supplementary notes

BLI: β-lactamase inhibitor; FabI: enoyl-acyl carrier protein reductase; FtsZ: filamenting temperature-sensitive Z.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Register now
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Leading companies trust Statista:
paypal google adobe pg samsung telekom
I think of Statista as Google for researchers. Statista provides you with the information you search for right away.
Dr. Horst Stipp

Dr. Horst Stipp
EVP, Research & Innovation, Advertising Research Foundation

Statistics on " Coronavirus: the pharma and medtech response "

Other statistics that may interest you Coronavirus: the pharma and medtech response

Pharma - before the pandemic

6

Treatments and vaccines

8

Focus: BioNTech and Moderna

7

Opinions on COVID-19 vaccines

6

Business impact

4

Medtech - before the pandemic

5

Ventilators and testing

7

Discover Statista

Need help with using Statista for your research? Tutorials and first steps
Do you have any questions about our business solutions?

We provide you with detailed information about our Professional Account.

Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Register now
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.